Loading
AT
Airsculpt Technologies, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Apr 2026.
Airsculpt Technologies, Inc.: what insiders have been doing
Airsculpt Technologies, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 22 filings, from 7 insiders.
No insider sold shares on the market over the period. Instead, the filings list 12 purchases totalling €1.7M, made by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €225k, bought by Chernett Jorey and made public on 16 March 2026. On the buying side, the filings list 1 major shareholder among the declarants.
The clock since the last published purchase (20 April 2026) now reads 181 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,814 companies, median 19 filings), a count of 22 filings is above the norm. Over the whole record (from 2021), the tally stands at 21 purchases and 4 sales. The 10-K/A for the year ended 31 December 2025 shows 151.8 m USD of revenue and -11.7 m USD of net income.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
81
Thresholds
n/a
Buy Volume
€4M
21 ops. · all time
Sell Volume
€25M
4 ops. · all time
Who traded when
BuySaleJorey Chernett12 buys
Aaron Rollins1 buy1 sale
Adam T. Feinstein1 buy
Dennis Dean1 sale
Yogesh Jashnani1 buy
Since the insiders bought
- +95.1%Entry US$2.45 · Close at T+90 US$4.78
- +1.9%Entry US$5.25 · Close at T+365 US$5.35
- +34.4%Entry US$3.91 · Close at T+365 US$5.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,490 of 24,148 companies
33.3
score / 100
Value30
Quality37
FCF yld0.4%
Earn yld-6.2%
EV/EBITDA·
ROE-12%
Gross mgn59%
Net mgn-7.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.60
Analyst consensus
2 analysts2.67/5
US$3.00Target US$4.50(+73%)US$6.00
Income statement
RevenueUS$151.8M
Gross profitUS$90.1M59% margin
EBITDAUS$1.2M1% margin
Net income-US$11.7M-7.8% margin
Valuation
PER (forward)-260.0x
P/Book1.8x
Beta2.37
Balance sheet & cash
Market capUS$187.4M
Total debtUS$83.6M
Free Cash FlowUS$692k
Debt / Equity67%
Profitability & ownership
ROE-12.0%
ROA-1.9%
% insiders42.1%
% institutions63.4%
Last declaration on 14 May 2026
Declarations81 total
100,286 shares0Common StockSEC:0001889114-26-000002:0
100,286 shares0Common StockSEC:0001705224-26-000002:0
100,286 shares0Common StockSEC:0001889258-26-000002:0
40,000 shares@ US$2.540.052% mcap5.2% of flowCommon StockSEC:0000921895-26-001030:0
Canonical exit: 16 Jul 2026 (T+90)
20,000 shares@ US$2.600.027% mcap2.6% of flowCommon StockSEC:0000921895-26-000989:0
Canonical exit: 13 Jul 2026 (T+90)
68,027 shares0Common Stock, $0.001 Par ValueSEC:0001104659-26-042161:0
238,095 shares0Common Stock, $0.001 Par ValueSEC:0001104659-26-042163:0
55,272 shares0Common Stock, $0.001 Par ValueSEC:0001584009-26-000002:0
60,000 shares@ US$2.939.0% of flowCommon StockSEC:0000921895-26-000944:0
Canonical exit: 6 Jul 2026 (T+90)
90,000 shares@ US$2.8213.2% of flowCommon StockSEC:0000921895-26-000915:0
Canonical exit: 2 Jul 2026 (T+90)
50,000 shares@ US$2.917.5% of flowCommon StockSEC:0000921895-26-000802:0
Canonical exit: 21 Jun 2026 (T+90)
40,000 shares@ US$2.775.7% of flowCommon StockSEC:0001193805-26-000307:0
Canonical exit: 18 Jun 2026 (T+90)
38,379 shares@ US$2.7957.2% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-26-032869:0
77,702 shares@ US$2.6410.7% of flowCommon StockSEC:0000921895-26-000752:0
Canonical exit: 17 Jun 2026 (T+90)
83,000 shares@ US$2.5611.1% of flowCommon StockSEC:0001193805-26-000283:0
Canonical exit: 15 Jun 2026 (T+90)
105,848 shares@ US$2.4313.5% of flowCommon StockSEC:0000921895-26-000696:0
Canonical exit: 14 Jun 2026 (T+90)
88,000 shares@ US$2.159.8% of flowCommon StockSEC:0000921895-26-000668:0
Canonical exit: 9 Jun 2026 (T+90)
45,600 shares@ US$2.004.7% of flowCommon StockSEC:0000921895-26-000638:0
Canonical exit: 4 Jun 2026 (T+90)
80,000 shares@ US$1.717.0% of flowCommon StockSEC:0000921895-26-000613:0
Canonical exit: 1 Jun 2026 (T+90)
24,217 shares@ US$2.5832.7% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-26-011081:0
147,059 shares0Common Stock, $0.001 Par ValueSEC:0001104659-26-007005:0
56,097 sharesCommon Stock, $0.001 Par ValueSEC:0001104659-25-103868:0
462,957 shares@ US$4.007.5% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-25-058584:0
Canonical exit: 7 Sept 2025 (T+90)
2,118 shares@ US$3.6020.1% of flowCommon Stock, $0.001 Par ValueSEC:0001104659-25-050994:0
Canonical exit: 17 Aug 2025 (T+90)
58,594 shares0Common StockSEC:0001104659-25-046310:0
25 of 81 declarations
About Airsculpt Technologies, Inc.
AirSculpt Technologies, Inc. is a United States-based company listed on the NASDAQ market under the ticker AIRS. It operates in the aesthetic healthcare space and focuses on premium body contouring procedures. The company’s core offering is a minimally invasive treatment platform designed to remove fat, tighten skin and reshape targeted areas of the body with a strong emphasis on precision, comfort and recovery speed. In its regulatory and investor materials, AirSculpt describes itself as a national provider of premium body contouring procedures delivered exclusively through its own offices and supported by surgeons, nurses and patient care consultants. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b))
Founded in 2012, AirSculpt is headquartered in Miami Beach, Florida, in the United States. The business is structured around AirSculpt Technologies, Inc. and its subsidiaries, with a vertically controlled model that combines proprietary medical procedures, standardized patient experience and a branded service format. The company’s flagship method, AirSculpt®, is presented as a patented, next-generation body contouring technology that is minimally invasive and does not require needles, scalpels, stitches or general anesthesia. This proprietary positioning is a key competitive differentiator versus more traditional cosmetic surgery providers. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b))
Read moreShow less
Its main service lines include a broad range of fat removal and fat transfer procedures. AirSculpt markets several branded treatments, including AirSculpt®, AirSculpt® +, AirSculpt® Smooth, Power BBL®, Up a Cup™ and Hip Flip™. AirSculpt® + combines fat removal with skin tightening, while AirSculpt® Smooth is designed to reduce cellulite. These offerings indicate that the company is not just selling a single procedure, but rather building a portfolio of proprietary aesthetic solutions aimed at different patient needs within the body-contouring category. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b))
Geographically, the company’s footprint is primarily in the United States, with an additional presence in Canada. Recent disclosures also show a strategic retrenchment abroad, including the closure of its London facility in 2025, suggesting management is focusing capital and operational attention on the most attractive markets. In early 2026, management also highlighted a refreshed go-to-market strategy, improved business processes and the launch of new procedures as part of efforts to reaccelerate growth. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b))
Recent operating trends point to a company in turnaround mode. In 2025, AirSculpt completed 11,852 procedures and reported revenue of $151.8 million, down from 2024. In April 2026, management reported sequential improvement in same-store sales and provided full-year 2026 guidance for approximately $151 million to $157 million in revenue and $15 million to $17 million in Adjusted EBITDA. From an investment perspective, AirSculpt remains a niche aesthetic-healthcare operator with a differentiated brand and proprietary procedures, but it also faces demand cyclicality and execution risk as it works to stabilize growth and improve profitability. ([investors.elitebodysculpture.com](https://investors.elitebodysculpture.com/node/8641/pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
